Michael Seckl
Overview
Explore the profile of Michael Seckl including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
242
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Branco-Silva M, Maesta I, Horowitz N, Elias K, Seckl M, Berkowitz R
Int J Gynecol Cancer
. 2024 Oct;
PMID: 39375166
Gestational trophoblastic neoplasia (GTN) is a group of rare but highly curable pregnancy-related tumors, especially in low-risk cases. However, around 25% of patients with GTN develop either resistant or recurrent...
2.
Lok C, Seckl M
Gynecol Obstet Invest
. 2024 Apr;
89(3):163-165.
PMID: 38679007
No abstract available.
3.
Bergamini A, Ramaswami R, Froeling F, Papanastasopoulos P, Short D, Aguiar X, et al.
Int J Gynecol Cancer
. 2023 Nov;
33(11):1750-1756.
PMID: 37931975
Objective: To assess fertility outcomes in long-term survivors of malignant ovarian germ cell tumors treated with fertility-sparing surgery with or without additional chemotherapy. Methods: Women diagnosed and treated for malignant...
4.
Joneborg U, Bergamini A, Wallin E, Mangili G, Solheim O, Marquina G, et al.
Int J Gynecol Cancer
. 2023 Oct;
33(10):1621-1626.
PMID: 37783481
Objective: To evaluate outcomes of European cross-border multidisciplinary tumor boards in terms of participation, adherence to treatment recommendations, and access to novel treatment strategies. Methods: The European reference network for...
5.
Baas I, Westermann A, You B, Bolze P, Seckl M, Ghorani E
Gynecol Obstet Invest
. 2023 Sep;
89(3):230-238.
PMID: 37703867
Background: Immune checkpoint immunotherapy (CPI) targeting programmed cell death 1 (PD-1)/ligand (PD-L1) has been shown to be an effective treatment for gestational trophoblastic neoplasia (GTN). This includes those with multidrug...
6.
Black L, Bowes A, Seckl M, Maher G, Kaur B, Arumainayagam J, et al.
Clin Case Rep
. 2023 Mar;
11(3):e7114.
PMID: 36998325
Epithelioid trophoblastic tumor (ETT) is a rare malignancy arising from neoplastic proliferation of chorionic-type intermediate trophoblasts. ETT poses significant challenges to clinicians in the diagnosis and treatment and can hence...
7.
Hennah L, Seckl M, Ghorani E
Int J Gynecol Cancer
. 2023 Mar;
33(3):414-419.
PMID: 36878565
The discovery that anti-programmed death-1 antibody (anti-PD-1) immunotherapy can cure patients with multidrug-resistant gestational trophoblastic neoplasia provides a new powerful and low toxicity treatment. This heralds an era within which...
8.
Younan H, Keogh G, Seckl M, Sarwar N
BMJ Case Rep
. 2023 Jan;
16(1).
PMID: 36599491
We present a case of a woman in her 20s, with a prior history of paediatric sacrococcygeal germ cell tumour, presenting with a 6-month history of perianal pain. An MRI...
9.
Merrick S, Nankivell M, Quartagno M, Clarke C, Joharatnam-Hogan N, Waddell T, et al.
Contemp Clin Trials
. 2022 Dec;
124:107030.
PMID: 36519749
Background: Immune checkpoint inhibitors (ICI) have revolutionised treating advanced cancers. ICI are administered intravenously every 2-6 weeks for up to 2 years, until cancer progression/unacceptable toxicity. Physiological efficacy is observed...
10.
Ramirez L, Maesta I, Bianconi M, Jankilevich G, Otero S, Mejia C, et al.
Rev Bras Ginecol Obstet
. 2022 Jun;
44(8):746-754.
PMID: 35760362
Objective: There are few multinational studies on gestational trophoblastic neoplasia (GTN) treatment outcomes in South America. The purpose of this study was to assess the clinical presentation, treatment outcomes, and...